Background-Myocardial contractile response to ␤ 1 -and ␤ 2 -adrenergic receptor (AR) stimulation is severely impaired in chronic heart failure, in which G i signaling and the ratio of ␤ 2 /␤ 1 are often increased. Because ␤ 2 -AR but not ␤ 1 -AR couples to G s and G i with the G i coupling negating the G s -mediated contractile response, we determined whether the heart failure-associated augmentation of G i signaling contributes differentially to the defects of these ␤-AR subtypes and, if so, whether inhibition of G i or selective activation of ␤ 2 -AR/G s by ligands restores ␤ 2 -AR contractile response in the failing heart. Methods and Results-Cardiomyocytes were isolated from 18-to 24-month-old failing spontaneously hypertensive (SHR) or age-matched Wistar-Kyoto (WKY) rat hearts. In SHR cardiomyocytes, either ␤-AR subtype-mediated inotropic effect was markedly diminished, whereas G i proteins and the ␤ 2 /␤ 1 ratio were increased. Disruption of G i signaling by pertussis toxin (PTX) enabled ␤ 2 -but not ␤ 1 -AR to induce a full positive inotropic response in SHR myocytes. Furthermore, screening of a panel of ␤ 2 -AR ligands revealed that the contractile response mediated by most ␤ 2 -AR agonists, including zinterol, salbutamol, and procaterol, was potentiated by PTX, indicating concurrent G s and G i activation. In contrast, fenoterol, another ␤ 2 -AR agonist, induced a full positive inotropic effect in SHR myocytes even in the absence of PTX. Conclusions-We conclude that enhanced G i signaling is selectively involved in the dysfunction of ␤ 2 -but not ␤ 1 -AR in failing SHR hearts and that disruption of G i signaling by PTX or selective activation of ␤ 2 -AR/G s signaling by fenoterol restores the blunted ␤ 2 -AR contractile response in the failing heart.
stimulation and, if so, to determine whether ␤ 2 -AR/G s selective activation by certain agonists is able to restore the contractile support by ␤-AR stimulation in the failing heart. Specifically, we (1) determined the abundance and function of both ␤-AR subtypes (␤ 1 -AR and ␤ 2 -AR) and G proteins (G s and G i ) in cardiomyocytes from spontaneously hypertensive rats (SHR) and age-matched Wistar-Kyoto rats (WKY), (2) investigated the potential role of G i signaling in the defects of ␤-AR subtype-mediated contractile response in failing SHR cardiomyocytes, (3) and screened a number of ␤ 2 -AR ligands to identify "␤ 2 -AR/G s -signaling-selective" agonists and tested the agonists in cardiomyocytes from failing SHR hearts.
Methods

Echocardiography and Hemodynamic Studies
Transthoracic echocardiographic studies were performed in rats as previously described. 23 Briefly, a 2D short-axis view of the left ventricle (LV) was obtained at the level of the papillary muscles. M-mode tracings were recorded through the anterior and posterior LV walls. The percentage shortening of the endocardium was calculated as (LVDDϪLVSD)/LVDDϫ100, where LVDD is LV internal diastolic dimension and LVDS is LV internal systolic dimension. The heart rates, blood pressures, and respiratory rates of all animals were monitored at monthly intervals. Blood pressure was measured by the tail-cuff method.
Measurement of Cardiac Myocyte Contraction
Myocytes were isolated from 18-to 24-month-old SHR or WKY rats by use of standard enzymatic techniques. 14 Cells were perfused with a HEPES buffer containing (in mmol/L): 137 NaCl, 5.4 KCl, 1.2 MgCl 2 , 1 NaH 2 PO 4 , 1 CaCl 2 , 20 glucose and 20 HEPES (pH 7.4) and electrically stimulated at 0.5 Hz at 23°C. Cell length was monitored by an optical edge-tracking method as previously described. 14 In a subset of experiments, aliquots of cells were incubated with PTX (1.5 g/mL at 37°C for 3 hours). 6 An individual myocyte was exposed to only 1 dose of 1 agonist, and measurements were obtained under steady-state conditions after a 10-minute exposure to the designated agonist.
Receptor Radioligand Binding
␤-AR radioligand binding studies were performed in membranes from LVs by use of the nonselective ␤-AR antagonist [ 125 I]-labeled cyanopindolol ( 125 I-CYP), as described previously. 15 Maximal binding (B max ) was measured by use of a saturating amount of 125 I-CYP on 25 g of membrane protein from LVs. Inclusion of 10 mol/L propranolol defined nonspecific binding. For competition isotherms, membranes (25 g total protein) were incubated with 50 pmol/L 125 I-CYP and increasing dilutions of ICI118,551 (ICI), a selective ␤ 2 -AR antagonist, as described previously. 15 The percentage of ␤ 2 -AR was calculated by use of GraphPad Prism.
Western Analysis of G s and G i Proteins
Cardiac membranes from myocytes were used to determine G s and G i protein amounts by Western analysis. 18 The antibodies recognizing the ␣-subunits of G i2 , G i3 , and G s were obtained from Santa Cruz Biotechnology.
Statistical Analysis
Results are expressed as meanϮSEM. Significance was determined by use of Student's t test, with a value of PϽ0.05 considered to be statistically significant.
Results
Chronic Heart Failure Model: SHR
SHRs develop hypertension at Ϸ6 to 8 weeks of age. By the age of 18 to 24 months, Ϸ50% of these rats develop severe dilated chronic heart failure, many aspects of which have been characterized. 24 At the time of study (ie, 18 to 24 months old), all SHRs used in this study had severe physical signs of heart failure (eg, resting tachycardia, tachypnea, pleural and/or pericardial effusions, and ascites). Cardiac dilation in the SHR group was evidenced by echocardiographic measurements (Table 1) . Cardiac hypertrophy was confirmed by significant increases in the heart weight/body weight ratio, by echocardiographic measurements of LV posterior wall thickness, and by increased resting cell length ( Table 1) .
Alterations in ␤-AR Density and G Protein Abundance in Failing SHR Hearts
We first examined total ␤-AR density, ␤ 1 -and ␤ 2 -AR subpopulations, and the abundance of G s and G i proteins in myocytes from 18-to 24-month-old SHR and age-matched WKY cardiac myocytes. There was a significant decrease (24%) in the B max in SHR relative to WKY hearts, without alterations in the binding affinity ( Table 2 ). To define the relative abundance of ␤ 1 -AR and ␤ 2 -AR, competition isotherms were performed by use of the selective ␤ 2 -AR antagonist ICI. The ␤ 2 /␤ 1 -AR ratio in control animals is 44/56, which is similar to the ratio previously reported. 15 The ␤ 2 /␤ 1 -AR ratio was significantly increased in SHR relative to WKY hearts ( Table 2 ). This result indicates that the reduction in total ␤-AR density is largely accounted for by the loss of ␤ 1 -AR. Thus, a selective downregulation of ␤ 1 -AR leads to a relative increase in the ␤ 2 -AR density in the failing SHR heart, a situation similar to what has been reported in failing human heart. [1] [2] [3] In addition, both G i2 and G i3 but not G s were elevated by Ϸ2-fold in SHR compared with WKY hearts (Figure 1 ), resulting in an increase in the G i /G s ratio, as is the case in human heart failure. [3] [4] [5] Taken together, these results suggest that the SHR heart failure model resembles human heart failure with respect to the major changes that occur in the proximal ␤-AR signaling system.
Disruption of G i Signaling by PTX Selectively Restores ␤ 2 -AR-but Not ␤ 1 -AR-Mediated Positive Inotropic Effect in Cardiomyocytes From Failing SHR Hearts
Although the baseline contraction amplitude in myocytes from failing SHR hearts was not significantly different from that of control animals (see Figure 2 legend), the positive inotropic effect of either ␤-AR subtype stimulation was markedly attenuated. Figure 2A shows that myocyte contractile response to ␤ 1 -AR stimulation by norepinephrine (NE) in the presence of ␣ 1 -AR and ␤ 2 -AR blockade by prazosin (10 Ϫ6 mol/L) and ICI (10 Ϫ7 mol/L), respectively, was markedly blunted in SHR myocytes compared with that in WKY cells, consistent with the downregulation of the receptor density. Figure 2B illustrates that ␤ 2 -AR stimulation by zinterol had only a minor positive inotropic effect in SHR ventricular myocytes, whereas it enhanced the contraction amplitude by Ͼ2-fold in control cardiomyocytes from age-matched WKYs. The dose-response curve of zinterol to increase contraction amplitude was severely shifted downward in SHR compared with WKY. Thus, myocyte contractile response to either ␤ 1 -AR or ␤ 2 -AR was overtly attenuated in SHR cardiomyocytes relative to WKY myocytes, even though only ␤ 1 -AR density was selectively downregulated, with little change in ␤ 2 -AR density in SHR hearts ( Table 2) .
To test the hypothesis that exaggerated G i signaling might be differentially involved in the impairment of ␤ 2 -AR versus that of ␤ 1 -AR in the failing heart, we treated myocytes with PTX to disrupt G i function. Remarkably, PTX not only enhanced the contractile response to ␤ 2 -AR stimulation in both failing SHR and control myocytes but also abolished the difference between the 2 groups ( Figure 2B ). In contrast, PTX did not affect the whole dose-response of ␤ 1 -AR stimulation by NE in either WKY or SHR myocytes ( Figure  2A ). These results indicate that enhanced G i signaling is specifically involved in the defect of ␤ 2 -AR contractile response but not in the dysfunction of ␤ 1 -AR signaling in the SHR heart failure model. These results also suggest that ␤ 2 -AR-coupled G s signaling remains largely intact in the failing heart.
Screening for Ligands Bypassing ␤ 2 -AR/G i Pathway
To determine whether disruption or avoidance of the ␤ 2 -ARcoupled G i signaling pathway is able to restore ␤ 2 -ARmediated contractile support in the failing SHR heart, we searched for ligands that activate ␤ 2 -AR-coupled G s signaling but not the G i pathway. Six known ␤ 2 -AR-selective agonists and 2 nonselective ␤-AR agonists were tested in the presence of the ␤ 1 -AR antagonist CGP20712A (CGP; 3ϫ10 Ϫ7 mol/L). Zinterol had been well characterized in previous studies as a selective ␤ 2 -AR agonist. 6 -9,10 -15 The specificity of other tested agonists, including salbutamol, procaterol, and fenoterol, for ␤ 2 -AR stimulation was verified by the fact that the highly selective ␤ 1 -AR antagonist CGP (3ϫ10 Ϫ7 mol/L) did not block their contractile responses, whereas it fully abolished the effect induced by the ␤ 1 -AR agonist NE (10 Ϫ7 mol/L) ( Figure 3 ). Cell contractile response to ␤-AR stimulation and its PTX sensitivity were then measured to represent the overall readout of G s (in PTXtreated cells) or combined G s -G i signaling (in non-PTXtreated cells).
Most ligands tested, including salbutamol, procaterol, and zinterol, enhanced the contraction amplitude of WKY myocytes in a dose-dependent manner, with a maximal increase of Ϸ2-fold ( Figure 4A through 4C) . Inhibition of G i function by PTX enabled the ␤ 2 -AR agonists to induce a full contractile response, with the maximal response being a 3-fold increase ( Figure 4A through 4C) . In other words, with respect to their inotropic effects, inhibition of G i signaling converted these partial ␤ 2 -AR agonists to full agonists. These results are consistent with previous findings that ␤ 2 -AR can simultaneously activate G s and G i . 6 -9 A similar potentiating effect of PTX was observed for ␤ 2 -AR stimulation induced by other known ␤ 2 -AR agonists such as terbutaline and celenbuterol, or by nonselective agonists, epinephrine and isoproterenol, plus the ␤ 1 -AR blocker CGP (data not shown). Interestingly, another selective ␤ 2 -AR agonist, fenoterol, 25 evoked a full contractile response that was insensitive to PTX treatment ( Figure 4D ). It appears that fenoterol selectively stimulates the ␤ 2 -AR/G s signaling pathway, whereas other ␤ 2 -AR agonists activate both G s and G i proteins in terms of their effects on cardiac myocyte contractility.
Rescue of the Depressed ␤ 2 -AR Contractile Response by Fenoterol in Myocytes From Failing SHR Hearts
We next determined whether the apparent ␤ 2 -AR/G s signaling-specific agonist fenoterol could rescue the diminished contractile response to ␤ 2 -AR stimulation in myocytes from failing SHR hearts. Figure 5A shows typical continuous recordings of myocyte contractile responses to zinterol or fenoterol. Fenoterol induced a robust increase in contraction amplitude in a representative SHR cell. This effect was completely reversed by the ␤ 2 -AR antagonist ICI (10 Ϫ7 mol/L), indicating that the positive inotropic effect of fenoterol is mediated by selective ␤ 2 -AR stimulation. In contrast, zinterol had a very minor effect in another cell from the same heart. Figure 5B shows the average dose-response of contraction amplitude to fenoterol in cardiomyocytes from SHR and age-matched WKY rats. The 2 dose-response curves virtually overlapped each other, in sharp contrast to the markedly suppressed contractile response to zinterol in failing SHR heart cells ( Figure 2B ). Thus, fenoterol is able to restore a full contractile response to ␤ 2 -AR stimulation in SHR myocytes even in the absence of PTX, thereby abolishing the difference between SHR and WKY.
Discussion
Enhanced G i Signaling Selectively Contributes to the Diminution of ␤ 2 -AR-but Not ␤ 1 -AR-Mediated Contractile Response in Myocytes From Failing SHR Hearts
Although previous studies have demonstrated that PTX treatment partially restores the diminished contractile response to mixed ␤-AR stimulation in a rat myocardial infarction heart failure model 26 and in myocytes from failing human hearts, 27 the present study provides the first documentation that enhanced G i signaling is, in fact, selectively involved in heart failure-associated attenuation in ␤ 2 -AR-but not ␤ 1 -ARmediated increase in myocyte contractility. This is because inhibition of ␤ 2 -AR/G i signaling by PTX treatment enables ␤ 2 -AR stimulation to induce a full contractile response, thus abolishing the difference between the failing and normal hearts, whereas it does affect ␤ 1 -AR-induced inotropic effect. These findings are consistent with our previous notion that ␤ 2 -AR but not ␤ 1 -AR dually couples to G s and G i and that the G i coupling exhibits an inhibitory effect on the G s signaling. 6 -9 Although the heart failure-associated defect of ␤ 2 -AR contractile response is largely attributable to enhanced ␤ 2 -AR/G i signaling, multiple mechanisms might be involved in ␤ 1 -AR dysfunction, including receptor downregulation 1-3 ( Table 2 ) and receptor desensitization resulting from upregulated G protein-coupled receptor kinases. In this regard, it has been shown that the level and enzymatic activity of ␤-AR kinase 1 (␤ARK1), a prototypic G protein-coupled receptor kinase, 28 are significantly elevated in human 29 and SHR failing hearts. 30 The increased ␤ARK1 abundance/activity may contribute to the reduced ␤ 1 -AR signaling in chronically failing hearts. Further studies are needed to determine the relative contributions of enhanced G i function and ␤ARK1 to subtype-specific defects of ␤-AR in the context of heart failure.
Selective Downregulation of ␤ 1 -AR May Serve as a Protective Mechanism in Heart Failure
It has been highly controversial as to whether enhancing ␤-AR signaling is beneficial or deleterious for the failing heart. The prevalent view is that chronically increasing nonselective ␤-AR stimulation is toxic to the heart, because there is an inverse relationship between the plasma level of catecholamines and survival in heart failure patients 31 and because ␤-AR blockade reduces both the morbidity and mortality in heart failure patients. 32 More recent studies have demonstrated that ␤ 1 -AR induces apoptosis in cultured rodent cardiomyocytes. 16 -19 Similarly, cardiac transgenic overexpression of ␤ 1 -AR in mice leads to marked myocyte hyper-trophy, apoptosis, and heart failure. 33, 34 Thus, chronic ␤ 1 -AR stimulation is detrimental to the myocardium.
In contrast, selective enhancement of ␤ 2 -AR signaling might be beneficial for the failing heart. This hypothesis is supported by the fact that ␤ 2 -AR stimulation protects cardiac myocytes against a wide array of apoptotic insults. 16 -19 In addition, overexpression of cardiac ␤ 2 -AR by 100-to 200fold does not induce hypertrophy or heart failure, 35 at least up to the age of 1 year. In fact, crossing transgenic mice overexpressing cardiac ␤ 2 -AR at appropriate levels (30-fold) with transgenic mice overexpressing G q␣ not only improves cardiac performance but also prevents hypertrophy in the G q␣ overexpression heart failure model, 36 although extremely high levels of ␤ 2 -AR overexpression induce pathological phenotypes 36, 37 and fail to rescue the genetic mouse heart failure model. 36, 37 Furthermore, the beneficial effect of ␤ 2 -AR stimulation in the context of heart failure is clearly supported by the analysis of polymorphisms of ␤ 2 -AR in chronic heart failure patients. The prognosis of heart failure patients with Ile164 polymorphism (a Thr-to-Ile switch at amino acid 164 with reduced ␤ 2 -AR signaling) 38 relative to patients without the ␤ 2 -AR variant is much worse, and they are significantly more likely to receive earlier aggressive interventions or cardiac transplantation. 39 In the present study, we found that in failing SHR hearts, ␤ 1 -AR is selectively downregulated with little or no loss of ␤ 2 -AR, similar to the situation of chronic human heart failure. [1] [2] [3] In light of evidence for the opposing effects of ␤ 1 -AR and ␤ 2 -AR stimulation on cardiac myocyte apoptosis 16 -19 and the distinct phenotypes of transgenic overexpression of ␤ 1 -AR versus ␤ 2 -AR, [33] [34] [35] the selective downregulation of ␤ 1 -AR may represent a cardiac protective mechanism to slow the progression of cardiomyopathy and contractile dysfunction.
Selective Activation of ␤ 2 -AR/G s Signaling in Failing SHR Hearts
Because heart failure in many instances is related to a selective loss of ␤ 1 -AR and because chronic stimulation of ␤ 2 -AR exhibits no known detrimental effects, as discussed above, 35 ␤ 2 -AR would appear to be a potentially important therapeutic target for the treatment of chronic heart failure. However, most of the commonly used nonselective ␤-AR agonists (eg, isoproterenol) cannot discriminate ␤ 2 -AR from ␤ 1 -AR. In addition, most ␤ 2 -AR agonists cannot discriminate ␤ 2 -AR-coupled G s signaling from G i signaling. The situation is even worse in chronically failing hearts with elevated G i signaling, such that ␤ 2 -AR stimulation by zinterol elicits only a minor contractile response (Figure 2) . To unmask the ␤ 2 -AR/G s signaling from the inhibition by G i , we identified fenoterol as an apparent ␤ 2 -AR/G s -selective agonist, as evidenced by the lack of PTX sensitivity of its positive inotropic effect (Figure 3 ). In cardiomyocytes from failing SHR hearts, fenoterol elicits a contractile response that is comparable to that in cells from nonfailing WKY heart cells (Figure 4 ). It is also noteworthy that there may be some advantages to use of fenoterol instead of ␤ 1 -AR agonists to provide contractile support in the failing heart. Our preliminary experiments have shown that, unlike ␤ 1 -AR stimulation, ␤ 2 -AR stimulation by fenoterol does not induce cardiac myocyte apoptosis (Zhu et al, unpublished data), although it increases cAMP/PKA signaling, perhaps because of distinct compartmentation of cAMP signal in response to different ␤-AR subtype activation. [11] [12] [13] 40, 41 Regarding receptor theory, the G s -specific ␤ 2 -AR stimulation, as demonstrated here for native ␤ 2 -AR in intact cardiomyocytes, provides new evidence to support the idea that there are multiple active conformational states for a given receptor [42] [43] [44] [45] and that ligands may lead the receptor to a subset of downstream signaling pathways (ligand-directed receptor trafficking). 45 In contrast to fenoterol, a wellcharacterized ␤ 2 -AR inverse agonist, ICI, can direct ␤ 2 -AR to a G i -coupled form and result in a negative inotropic effect in cardiomyocytes from failing human hearts or rabbit and mouse myocytes in which ␤ 2 -AR and/or G i proteins are overexpressed. 44 In summary, the present study reveals 3 major findings. First, enhanced G i signaling is selectively involved in the dysfunction of ␤ 2 -AR but not of ␤ 1 -AR. Inhibition of G i signaling with PTX enables ␤ 2 -AR stimulation to induce a full contractile response in myocytes from failing SHR hearts without affecting ␤ 1 -AR contractile response. Second, ␤ 2 -AR-coupled G s and G i pathways appear to be activated in an agonist-dependent manner. Most agonists tested stimulate both pathways, whereas fenoterol predominantly activates G s signaling, as manifested by the lack of PTX sensitivity of its positive inotropic effect. Third, the apparent ␤ 2 -AR/G sselective agonist fenoterol fully restores ␤ 2 -AR contractile response in failing SHR hearts. Therefore, we conclude that enhanced G i signaling is specifically involved in the dysfunction of ␤ 2 -AR but not of ␤ 1 -AR in regulating myocyte contractility in the failing heart and that an apparent selective activation of ␤ 2 -AR-coupled G s , bypassing the G i pathway, provides a novel means to restore the diminished ␤ 2 -AR responsiveness in the SHR heart failure model. Thus, signaling-selective receptor stimulation by agonists may offer a wide range of novel therapeutic opportunities by enhancing the desired effects while avoiding the adverse side effects of therapeutic agents.
